Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1308A versus other pembrolizumab-based regimens in MSI-H/dMMR stage IV colorectal cancer
2022-502100-70-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 22
01
Overview
Phase 3, randomised trial of quavonlimab + pembrolizumab, mk-4830, vibostolimab + pembrolizumab, pembrolizumab and favezelimab + pembrolizumab in colorectal cancer (CRC) (5 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Jun 2021; status: completed.
02
Drugs
quavonlimab + pembrolizumabmk-4830vibostolimab + pembrolizumabpembrolizumabfavezelimab + pembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2022-502100-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502100-70-00.